The U.S. Food and Drug Administration has approved Jobevne (bevacizumab-nwgd), a biosimilar to Avastin (bevacizumab) for ...

To grow, cancer tumors must hijack the immune system for their needs. One of the main tricks that most tumors use is to ...

This phenomenon brings into focus long-standing questions about the stage at which cancer cells acquire metastatic abilities, the relationship of metastatic cells to their tumour of origin ...

The report forecasts global market growth from $116.1 billion in 2024 to $168 billion by 2029 at a CAGR of 7.7%. Highlighting advances in immunothera ...

Espin induces abundant filopodia formation at the leading edge and along the sides, exerting force for cells migrating in ...

In April 2025, Amgen announced a study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose ...

The Ontario Institute for Cancer Research (OICR) has announced its support for five Ontario research teams working to develop the next generation of medicines that kill tumours more effectively, cause ...

Genmab has announced that the European Commission (EC) has approved Tivdak (tisotumab vedotin) to treat recurrent or ...

Genmab (GMAB) announced that the European Commission has granted marketing authorization for TIVDAK, an antibody-drug conjugate, as monotherapy ...

Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy ...

Key Highlights: <li /> Global first immuno + anti-vascular bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC.